De novo loss-of-function mutations in SCN1A are the main cause of Dravet syndrome, a catastrophic encephalopathy characterized by recurrent early-life febrile seizures, a number of other afebrile seizure types that are often refractory to treatment, and behavioral abnormalities including social deficits, motor dysfunction, and cognitive impairment. We previously demonstrated that the reversible acetylcholinesterase inhibitor, Huperzine A, increases seizure resistance in Scn1a mutants. In the present study, we evaluated the therapeutic potential of donepezil, a reversible acetylcholinesterase inhibitor approved by the Food and Drug Administration, in a mouse model of Dravet syndrome (Scn1a +/À ). We found that donepezil conferred robust protection against induced seizures in Scn1a +/À mutants.
Introduction
Reversible acetylcholinesterase (AChE) inhibitors (e.g., donepezil, galantamine, and rivastigmine) are most widely used in the treatment of dementia and Alzheimer's disease (AD). 1 Donepezil, a synthetic reversible AChE inhibitor, also shows efficacy in rodent models of AD, 2, 3 neuropathic pain, 4 and autism. 5 In rodent studies, donepezil is more effective at penetrating the brain and has slower brain clearance compared to galantamine, 6 resulting in longer lasting effects. In addition, donepezil primarily inhibits AChE, whereas galantamine lacks specificity and can modulate other neurotransmitters (e.g., glutamate, dopamine, serotonin). 7 There is evidence to suggest that reversible AChE inhibitors might also be beneficial in the treatment of epilepsy. Donepezil, galantamine, and Huperzine A (Hup A), a naturally occurring reversible AChE inhibitor, have been shown to protect against soman-induced seizures. [8] [9] [10] [11] [12] [13] Hup A also provides protection against N-methyl-Daspartate (NMDA)-induced status epilepticus (SE) 14 and pentylenetetrazole (PTZ)-induced seizures in rats 15 and zebrafish. 16 In addition, we recently demonstrated that Hup A confers robust protection against induced seizures in Scn1a +/À and Scn1a RH/+ mouse models of Dravet syndrome (DS) and genetic epilepsy with febrile seizures plus (GEFS+), respectively. 17 Since Hup A effectively increased seizure resistance, we hypothesize that other reversible AChE inhibitors, such as donepezil, may also be efficacious in the treatment of epilepsy.
Although the effect of donepezil on spontaneous seizures was not examined, it was recently demonstrated that administration of donepezil following pilocarpine-induced SE protected against hippocampal neuron loss. 18 Furthermore, donepezil also protects against glutamate neurotoxicity.
19 Although the primary goal in the clinical management of epilepsy is often the prevention of seizures, patients with epilepsy often have cognitive and behavioral abnormalities that can significantly impact quality of life. Donepezil has been shown to improve social preference and increase social interaction in a mouse model of autism, 5 suggesting that it could also potentially ameliorate behavioral comorbidities in epilepsy. The few studies that have evaluated the effect of donepezil on memory in patients with epilepsy have been inconsistent. For example, in patients with partial seizures, donepezil (10 mg/day for 2 months) was shown to improve word recall 20 ; however, Hamberger et al. found no effect of donepezil (10 mg/day for 3 months) on memory in epileptic patients 21 . Moreover, both studies reported mild gastrointestinal issues and insomnia, but importantly, no significant increase in seizure frequency. 20, 21 De novo loss-of-function mutations in the voltagegated sodium channel (VGSC) SCN1A (encoding Na v 1.1) are the main cause of DS (OMIM 607208), an early-life encephalopathy characterized by recurrent early-life febrile seizures (FSs), and several other seizure types, including generalized tonic-clonic (GTCS), myoclonic, and partial seizures. These seizures are often refractory to treatment. Furthermore, patients with DS often have comorbid abnormalities, including motor dysfunction, social deficits, and cognitive impairment. [22] [23] [24] SCN1A mutations also lead to GEFS+, which is an inherited disorder characterized by FSs that persist beyond early childhood and the development of adult epilepsy. 25, 26 We and others have shown that mice with Scn1a mutations recapitulate many clinical features, including the development of spontaneous seizures. 27, 28 In the current study, we evaluated the therapeutic potential of donepezil in a mouse model of DS.
Materials and Methods

Animals
Male CF1 mice (Strain: 023, Charles River, 2-3 months old) were used to generate a dose-response curve based on seizures induced by the 6 Hz seizure induction paradigm. CF1 mice were also used to test the contribution of muscarinic and GABA A receptors to the observed donepezil-mediated seizure protection using the 6 Hz paradigm. Heterozygous Scn1a knockout mice (Scn1a
) were generated as previously described 27 
Donepezil administration
Donepezil hydrochloride (Sigma-Aldrich) was dissolved in sterile saline (0.9%). For acute administration, donepezil (10 mL/kg) or vehicle (0.9 % sterile saline) was administered via intraperitoneal (i.p.) injection 1 h prior to seizure induction. See supplemental for additional methods.
Results
Donepezil protects against induced seizures in CF1 mice
We first evaluated the effect of donepezil (1-10 mg/kg) on 6 Hz-induced seizures (44 mA) in male CF1 WT mice (N = 10/group). All vehicle-treated mice (N = 10) exhibited 6 Hz seizures consisting of forelimb clonus and paw waving (RS2 seizures). However, administration of 5.6 and 10 mg/kg donepezil significantly reduced seizure occurrence, whereby 4/10 and 5/10 treated mice were completely protected against 6 Hz-induced seizures, respectively (Fig. 1A) . However, significant adverse effects (lethargy, tremor, and approximately 30% mortality) were observed at 10 mg/kg donepezil; therefore, the 5.6 mg/kg dose was used for all subsequent experiments. The ability of donepezil (5.6 mg/kg) to protect against MES-induced seizures was also examined (N = 10/group, Fig. 1B ). Maximal seizures characterized by hindlimb extension were observed in all vehicle-treated mice following MES induction; however, 80% (8/10) donepezil-treated mice were protected against MES-induced hindlimb extension.
Central muscarinic and GABA A receptors contribute to the observed donepezilmediated seizure protection
To gain insight into the potential mechanism(s) by which donepezil mediates seizure protection, we coadministered donepezil and either a muscarinic or GABA A receptor antagonist prior to 6 Hz seizure induction in CF1 mice ( Fig. 1C and D) . These two antagonists were selected as we previously showed that Hup A-mediated seizure protection works, in part, through these two receptors 17 . Control mice were similarly handled and administered two injections of vehicle. Block of central muscarinic receptors was achieved by administration of scopolamine hydrobromide (SH, Fig. 1C ). Behavioral seizure responses were comparable between control mice that received vehicle and mice that received SH plus vehicle, demonstrating that SH alone does not alter the behavioral seizure response (Fig. 1C) . Seventy-five percent (6/8) of mice administered donepezil plus vehicle were completely protected against 6 Hz-induced seizures (6 RS0, 2 RS1, Fig. 1C) . In contrast, all mice administered donepezil plus SH exhibited seizures (6 RS2, 2 RS3, Fig. 1C ), demonstrating that centrally located muscarinic receptors contribute to donepezil-mediated seizure protection. Control mice administered PTZ (25 mg/kg) plus vehicle exhibited comparable seizure responses to mice that received only vehicle, demonstrating that this dose of PTZ does not alter the seizure response (Fig. 1D) . Only 1/8 mice administered donepezil plus PTZ was protected against 6 Hz-induced seizures (1 RS0, 1 RS1, 6 RS2), demonstrating that donepezil-mediated seizure protection also works, in part, by activation of GABA A receptors.
Donepezil increases resistance to induced seizures in Scn1a
+/À mutants
Since we observed seizure protection in CF1 WT mice, we next tested donepezil in Scn1a +/À mutants and WT littermates. We first determined the effect of 5.6 and 10 mg/kg donepezil on brain AChE activity in the WT littermates 1 h after administration. When compared to vehicle-treated mice, we observed 21% and 46% reduction in AChE activity with 5.6 and 10 mg/kg donepezil, respectively (N = 3-4/group, Fig. 2A ). We next evaluated the effect of donepezil against induced seizures in Scn1a +/À mutants and WT littermates. mutants were protected (9 RS0, 4 RS2). We next assessed the ability of donepezil to protect against MES-induced seizures in both sexes of Scn1a +/À mutants and WT littermates ( Fig. 2C and D) . As expected, all vehicle-treated A. B.
C. D.
G.
E. F.
H. I. Approximately 50% of donepezil-treated mice, regardless of genotype, did not exhibit a PTZ-induced GTCS, whereas all vehicle-treated mice exhibited a GTCS. Two-way ANOVA followed by Holms-S ıd ak's multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
mice, regardless of sex and genotype, exhibited a maximal seizure characterized by hindlimb extension. Following the administration of donepezil, protection was observed in 4/ 10 and 7/7 male WT littermates and Scn1a +/À mutants, respectively (Fig. 2C) . Similarly, protection against hindlimb extension was observed in 6/10 and 8/10 donepeziltreated female WT littermates and Scn1a +/À mutants, respectively (Fig. 2D) . Febrile seizures are commonly observed in patients with SCN1A-derived epilepsy. FS susceptibility in Scn1a mutant mice was examined by elevating the core body temperature of each mouse until the first GTCS was observed. We observed no difference in the temperature at which the Scn1a +/À mutant mice exhibited seizures following donepezil or vehicle administration ( Fig. 2E and F) . Finally, we evaluated the ability of donepezil to protect against PTZ-induced seizures. We observed no significant effect of donepezil on the latency to the first myoclonic jerk in Scn1a +/À mutants and WT littermates following PTZ administration (100mg/kg, Fig. 2G ). However, donepezil-treated WT littermates and Scn1a +/À mutants exhibited significantly increased latencies to the first GTCS ( Fig. 2H and I) . Furthermore, 4/11 and 3/11 donepeziltreated WT littermates and Scn1a +/À mutants did not exhibit a GTCS, demonstrating that donepezil provides robust protection against PTZ-induced seizures.
Discussion
Recent evidence suggests that reversible AChE inhibitors, such as Huperzine A and donepezil, may be therapeutic in epilepsy as evidenced by their ability to increase resistance to induced seizures [8] [9] [10] [11] 15, 17 . When compared to Hup A, donepezil similarly conferred robust protection against 6 Hz-, MES-, and PTZ-induced seizures. However, unlike Hup A, donepezil was not able to increase resistance to hyperthermia-induced seizures in Scn1a
Several observations suggest that the relative protective effects of donepezil and Hup A are not solely due to the reduction in AChE activity. First, we found that the highest levels of seizure protection were achieved at doses of 5.6 mg/kg donepezil and 1 mg/kg Hup A, which decreased AChE activity by 21% and 70% 17 , respectively. Second, we observed 30% mortality with 10 mg/kg donepezil, which reduced AChE activity by 46%. However, no mortality was observed when Hup A was administered at 1 mg/kg. Third, lower doses of Hup A (0.1 and 0.18 mg/kg) reduced AChE activity by approximately 30%; however, these doses of Hup A did not provide protection against induced seizures 17 . Finally, we previously demonstrated that Hup A-mediated seizure protection is also regulated by activation of muscarinic cholinergic receptors, and in part, by GABA A receptors 17 . Consistent with this, we also observed that the protection following donepezil administration relies on contribution of both the muscarinic cholinergic and GABA A receptors.
In summary, we have demonstrated the ability of donepezil to increase seizure resistance in SCN1A-derived epilepsy. Together with our previous findings with Hup A, these results provide additional support that reversible AChE inhibitors might be efficacious in SCN1A-derived epilepsy and possibly other forms of refractory epilepsy.
